| Year |
Citation |
Score |
| 2022 |
Ren J, Qu R, Rahman NT, Lewis JM, King ALO, Liao X, Mirza FN, Carlson KR, Huang Y, Gigante S, Evans B, Rajendran BK, Xu S, Wang G, Foss FM, et al. Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations. Blood Advances. PMID 35947128 DOI: 10.1182/bloodadvances.2022008168 |
0.305 |
|
| 2022 |
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, et al. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 20: 285-308. PMID 35276674 DOI: 10.6004/jnccn.2022.0015 |
0.322 |
|
| 2022 |
Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety. 1-8. PMID 35129014 DOI: 10.1080/14740338.2022.2036120 |
0.324 |
|
| 2021 |
Johnston PB, Cashen AF, Nikolinakos PG, Beaven AW, Barta SK, Bhat G, Hasal SJ, De Vos S, Oki Y, Deng C, Foss FM. Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma. Experimental Hematology & Oncology. 10: 15. PMID 33602316 DOI: 10.1186/s40164-021-00203-8 |
0.342 |
|
| 2021 |
King ALO, Mirza FN, Lewis JM, Carlson KR, Huntington S, Foss FM, Girardi M. B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma. Jaad Case Reports. 8: 89-92. PMID 33537387 DOI: 10.1016/j.jdcr.2020.12.025 |
0.334 |
|
| 2020 |
Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma. 1-8. PMID 32835553 DOI: 10.1080/10428194.2020.1808208 |
0.331 |
|
| 2020 |
Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma, Myeloma & Leukemia. PMID 32727701 DOI: 10.1016/J.Clml.2020.06.014 |
0.35 |
|
| 2020 |
Foss FM, Wang XV, Luger SM, Jegede O, Miller KB, Stadtmauer EA, Whiteside TL, Avigan DE, Gascoyne RD, Arber D, Wagner H, Strair RK, Hogan WJ, Sprague KA, Lazarus HM, et al. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion. PMID 32654201 DOI: 10.1111/Trf.15798 |
0.385 |
|
| 2020 |
Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma. 1-7. PMID 32643494 DOI: 10.1080/10428194.2020.1790555 |
0.436 |
|
| 2020 |
Lansigan F, Horwitz SM, Pinter-Brown LC, Carson KR, Shustov AR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Foss FM. Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study. Clinical Lymphoma, Myeloma & Leukemia. PMID 32532611 DOI: 10.1016/J.Clml.2020.05.001 |
0.376 |
|
| 2020 |
Yumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Advances. 4: 2213-2226. PMID 32437546 DOI: 10.1182/Bloodadvances.2020001756 |
0.414 |
|
| 2020 |
Zic JA, Ai W, Akilov OE, Carter JB, Duvic M, Foss F, Girardi M, Gru AA, Kim E, Musiek A, Olsen EA, Schieke SM, Shinohara M, Zain JM, Geskin LJ. Recommendations for Treatment of Cutaneous Lymphomas During the COVID-19 Pandemic. Journal of the American Academy of Dermatology. PMID 32305443 DOI: 10.1016/J.Jaad.2020.04.049 |
0.306 |
|
| 2020 |
Mirza F, Yumeen S, Lewis J, King A, Kim S, Carlson K, Foss F, Girardi M. 110 RNA expression analysis in stage IVA-B cutaneous T-cell lymphoma to identify novel biomarkers of prognosis and diagnosis Journal of Investigative Dermatology. 140: S13. DOI: 10.1016/J.Jid.2020.03.113 |
0.339 |
|
| 2020 |
Isufi I, Chandhok N, Boddu P, Pucar D, Seropian SE, Gowda L, Perreault S, Wilson LD, Roberts K, Foss FM. Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant Biology of Blood and Marrow Transplantation. 26: S244. DOI: 10.1016/J.Bbmt.2019.12.492 |
0.303 |
|
| 2019 |
Foss FM, Horwitz SM, Civallero M, Bellei M, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Montoto S, Chiattone C, Moskowitz A, et al. Incidence and Outcomes of Rare T cell Lymphomas from the T Cell Project: Hepatosplenic, Enteropathy Associated and Peripheral Gamma Delta T cell Lymphomas. American Journal of Hematology. PMID 31709579 DOI: 10.1002/Ajh.25674 |
0.466 |
|
| 2019 |
Wang M, Kibbi N, Ring N, Siddon A, Foss F, Totonchy M. DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma. Case Reports. 12. PMID 31570354 DOI: 10.1136/Bcr-2019-230641 |
0.323 |
|
| 2019 |
Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, Shanbhag S, Sokol L, Fling SP, Ramchurren N, Pierce R, Davis A, Shine R, Li S, Fong S, et al. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901056. PMID 31532724 DOI: 10.1200/Jco.19.01056 |
0.313 |
|
| 2019 |
Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, ... ... Foss FM, et al. Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Acta Haematologica. 1-11. PMID 31315113 DOI: 10.1159/000500666 |
0.418 |
|
| 2019 |
Afifi S, Mohamed S, Zhao J, Foss F. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma. Expert Opinion On Drug Safety. PMID 31303060 DOI: 10.1080/14740338.2019.1643837 |
0.45 |
|
| 2019 |
Foss FM, Parker TL, Girardi M, Li A. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate. Leukemia & Lymphoma. 1-4. PMID 31119966 DOI: 10.1080/10428194.2019.1612061 |
0.472 |
|
| 2019 |
Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Horwitz SM, Lansigan F, Pinter-Brown LC, Pro B, Shustov AR, Foss FM, Jain S. Single Agents Versus Combination Chemotherapy in Relapsed and Refractory Peripheral T-cell Lymphoma: Results from the Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) Registry. American Journal of Hematology. PMID 30896890 DOI: 10.1002/Ajh.25463 |
0.443 |
|
| 2019 |
O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, ... ... Foss F, et al. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800899. PMID 30707661 DOI: 10.1200/Jco.18.00899 |
0.438 |
|
| 2019 |
Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. PMID 30694529 DOI: 10.1002/Cncr.31861 |
0.436 |
|
| 2019 |
Gowda L, Foss F. Hepatosplenic T-Cell Lymphomas. Cancer Treatment and Research. 176: 185-193. PMID 30596219 DOI: 10.1007/978-3-319-99716-2_9 |
0.452 |
|
| 2019 |
Miccio JA, Wilson LD, Kann BH, Jairam V, Beckta J, Foss FM, Yeboa DN. Cutaneous T-Cell Lymphoma: Trends in Radiation Doses and Patterns of Care 2004-2015. Anticancer Research. 39: 253-259. PMID 30591466 DOI: 10.21873/Anticanres.13105 |
0.357 |
|
| 2019 |
Chandhok NS, Huntington SF, Isufi I, Gowda L, Xu ML, Bar N, Seropian S, Foss FM. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation Blood. 134: 4055-4055. DOI: 10.1182/Blood-2019-128888 |
0.433 |
|
| 2019 |
Witzig TE, Sokol L, Foss FM, Kim W, Jacobsen E, De La Cruz MdF, Caballero D, Advani RH, Roncero JM, de Oña R, Marin Niebla A, Rodriguez Izquierdo A, Terol MJ, Domingo-Domenech E, Piris MA, et al. Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study Blood. 134: 468-468. DOI: 10.1182/Blood-2019-128513 |
0.384 |
|
| 2019 |
Shallis RM, Bewersdorf JP, Gowda L, Podoltsev NA, Prebet T, Gore SD, Halene S, Isufi I, Foss FM, Huntington SF, Kim TK, Pillai MM, Parker TL, Neparidze N, Bar N, et al. Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience Blood. 134: 1330-1330. DOI: 10.1182/Blood-2019-127422 |
0.366 |
|
| 2019 |
Bewersdorf JP, Shallis RM, Diadamo A, Gowda L, Podoltsev NA, Gore SD, Prebet T, Halene S, Isufi I, Foss FM, Huntington SF, Kim TK, Pillai MM, Parker TL, Neparidze N, et al. Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought? Blood. 134: 5174-5174. DOI: 10.1182/Blood-2019-127277 |
0.352 |
|
| 2019 |
Bewersdorf JP, Shallis RM, Gowda L, Hager K, Podoltsev NA, Gore SD, Prebet T, Halene S, Isufi I, Foss FM, Huntington SF, Kim TK, Pillai MM, Parker TL, Neparidze N, et al. Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience Blood. 134: 5173-5173. DOI: 10.1182/Blood-2019-127162 |
0.324 |
|
| 2019 |
Mato AR, Schuster SJ, Foss FM, Isufi I, Ding W, Brander DM, Sitlinger A, Tun HW, Alhaj Moustafa M, Kennard K, King CM, Koehler A, Aitken C, He W, Kearney A, et al. A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas Blood. 134: 810-810. DOI: 10.1182/Blood-2019-126192 |
0.406 |
|
| 2019 |
Poh C, Frankel P, Ruel C, Abedi M, Schwab E, Costello CL, Zain J, Budde LE, William BM, Foss FM, Jonas BA, Rosenberg AS, Newman E, Tuscano J. Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis Blood. 134: 760-760. DOI: 10.1182/Blood-2019-124254 |
0.475 |
|
| 2019 |
Hollebecque A, Assouline S, Samaniego F, You B, Foss F, Prica A, Gordon SW, Webster M, Dyer MJ, El-Sharkawi D, Shapiro GI, Nabell L, Blagden SP, Lister J, Ulahannan SV, et al. Abstract A072: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A072 |
0.405 |
|
| 2019 |
Mehta A, Hollebecque A, Foss F, Lister J, Mita M, Wagner-Johnston N, Dyer M, You B, Prica A, Hernandez-Llizaliturri F, Ferraldeschi R, Chan D, Zhang J, Samaniego F. PS1073 PRELIMINARY RESULTS OF ASTX660, A NOVEL NON-PEPTIDOMIMETIC CIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA Hemasphere. 3: 486. DOI: 10.1097/01.HS9.0000562584.48238.C8 |
0.317 |
|
| 2019 |
Witzig T, Sokol L, Kim W, Foss F, Jacobsen E, de la Cruz Vicente F, Caballero D, Advani R, Roncero Vidal M, Niebla A, Rodriguez Izquierdo A, de Ona Navarrete R, Jose Terol M, Domingo-Domenech E, Rodriguez M, et al. S869 TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE 2 STUDY Hemasphere. 3: 389. DOI: 10.1097/01.hs9.0000561756.23393.6d |
0.302 |
|
| 2019 |
Perreault S, McManus D, Pulk R, Topal JE, Foss F, Isufi I, Seropian S, Bar N. 2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT) Open Forum Infectious Diseases. 6: S947-S947. DOI: 10.1093/Ofid/Ofz360.2371 |
0.352 |
|
| 2019 |
Yumeen S, King A, Kim S, Lewis J, Carlson K, Umlauf S, Surovtseva Y, Foss F, Girardi M. 676 Exploring novel therapeutic targets in the treatment of cutaneous T-cell lymphoma Journal of Investigative Dermatology. 139: S116. DOI: 10.1016/J.Jid.2019.03.752 |
0.391 |
|
| 2019 |
Boddu P, Perreault S, Isufi I, Chandhok N, Kim TK, Pillai M, Bar N, Prebet T, Zeidan A, Zelterman D, Seropian SE, Gowda L, Foss FM. Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience Biology of Blood and Marrow Transplantation. 25: S387. DOI: 10.1016/J.Bbmt.2018.12.796 |
0.463 |
|
| 2019 |
Shallis RM, Gleeson S, Chokr N, Fangyong L, Wei W, Azar M, Schulz W, Summers D, Hendrickson J, Foss F, Isufi I, Kim TK, Pillai M, Snyder E, Seropian S, et al. Restrictive Transfusions in the Era of Pathogen-Inactivated Platelets: A Single Center Experience Biology of Blood and Marrow Transplantation. 25: S365. DOI: 10.1016/J.Bbmt.2018.12.591 |
0.378 |
|
| 2019 |
Horwitz S, Foss F, Porcu P, Moskowitz A, Mehta-Shah N, Jacobsen E, Khodadoust M, Kim Y, Weinstock D, Lustgarten S, Baglio M, Youssoufian H, Brammer J. Duvelisib, an oral dual PI3K-δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T-cell lymphoma: rationale for the phase 2 PRIMO trial Hematological Oncology. 37: 65-66. DOI: 10.1002/Hon.33_2629 |
0.407 |
|
| 2019 |
Samaniego F, Hollebecque A, Foss F, Lister J, Mita M, Wagner-Johnston N, Dyer M, You B, Prica A, Hernandez-Llizaliturri F, Ferraldeschi R, Chan D, Zhang J, Mehta A. PRELIMINARY RESULTS OF ASTX660, A NOVEL NON-PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA Hematological Oncology. 37: 527-527. DOI: 10.1002/Hon.211_2631 |
0.429 |
|
| 2018 |
Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS. Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800359. PMID 30359156 DOI: 10.1200/Jco.18.00359 |
0.349 |
|
| 2018 |
Foss FM, Parker TL, Girardi M, Li A. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate. Clinical Lymphoma, Myeloma & Leukemia. PMID 30181105 DOI: 10.1016/J.Clml.2018.06.020 |
0.456 |
|
| 2018 |
O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, et al. Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a Phase 1 study. American Journal of Hematology. PMID 30094870 DOI: 10.1002/Ajh.25243 |
0.412 |
|
| 2018 |
Kim SR, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition. Oncotarget. 9: 29193-29207. PMID 30018745 DOI: 10.18632/Oncotarget.25670 |
0.418 |
|
| 2018 |
Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, Pileri S, Ko YH, Cabrera ME, Horwitz S, Kim WS, Shustov A, Foss FM, Nagler A, Carson K, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. British Journal of Haematology. PMID 29672827 DOI: 10.1111/Bjh.15258 |
0.403 |
|
| 2018 |
Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Martinez V, Montoto S, Chiattone C, et al. The outcome of peripheral T-cell lymphoma patients failing first line therapy: a report from the prospective, international T-Cell project. Haematologica. PMID 29599200 DOI: 10.3324/haematol.2017.186577 |
0.328 |
|
| 2018 |
Foss FM, Parker T. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma. The Oncologist. PMID 29438091 DOI: 10.1634/Theoncologist.2017-0658 |
0.472 |
|
| 2018 |
Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 18: e85-e93. PMID 29223388 DOI: 10.1016/J.Clml.2017.11.004 |
0.41 |
|
| 2018 |
Querfeld C, Foss FM, Kim YH, Pinter-Brown L, William BM, Porcu P, Pacheco T, Haverkos BM, DeSimone J, Guitart J, Halwani AS, Eradat HA, Huen A, Schroeder K, Pestano LA, et al. Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma Blood. 132: 2903-2903. DOI: 10.1182/Blood-2018-99-119861 |
0.321 |
|
| 2018 |
Khodadoust MS, Rook A, Porcu P, Foss FM, Moskowitz AJ, Shustov AR, Shanbhag S, Sokol L, Fling SP, Li S, Davis A, Fong S, Kim J, Yang Y, Yearley JH, et al. Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Final Results from a Phase 2 Multicenter Study Blood. 132: 2896-2896. DOI: 10.1182/Blood-2018-99-117244 |
0.327 |
|
| 2018 |
Witzig TE, Sokol L, Jacobsen ED, Kim W, Foss FM, Advani RH, Roncero Vidal JM, Marin Niebla A, Rodriguez Izquierdo A, De Ona Navarrete R, de la Cruz Vicente F, Caballero D, Mondejar R, Piris MA, Curry R, et al. Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study Blood. 132: 2937-2937. DOI: 10.1182/Blood-2018-99-116277 |
0.38 |
|
| 2018 |
Stuver R, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Lansigan F, Pinter-Brown LC, Pro B, Shustov AR, Horwitz SM, Foss FM, Jain S. Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry Blood. 132: 2926-2926. DOI: 10.1182/Blood-2018-99-112869 |
0.433 |
|
| 2018 |
Dehner C, Ruff W, Foss F, Girardi M, Kriegel M. LB1550 Skin commensals as instigators of cutaneous T cell lymphoma Journal of Investigative Dermatology. 138: B14. DOI: 10.1016/J.Jid.2018.06.086 |
0.369 |
|
| 2017 |
Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, ... ... Foss FM, et al. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma. Blood. PMID 29233821 DOI: 10.1182/Blood-2017-08-802470 |
0.455 |
|
| 2017 |
Cyrenne BM, Subtil A, Girardi M, Foss F. Primary cutaneous aggressive epidermotropic cytotoxic CD8(+) T-cell lymphoma: long-term remission after brentuximab vedotin. International Journal of Dermatology. PMID 29047111 DOI: 10.1111/Ijd.13792 |
0.362 |
|
| 2017 |
Cyrenne BM, Lewis J, Weed J, Carlson K, Mirza FN, Foss F, Girardi M. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood. PMID 28972015 DOI: 10.1182/Blood-2017-06-792150 |
0.456 |
|
| 2017 |
Foss F, Horwitz S, Pro B, Miles Prince H, Sokol L, Balser B, Wolfson J, Coiffier B. Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. Journal of Hematology & Oncology. 10: 154. PMID 28923081 DOI: 10.1186/s13045-017-0518-8 |
0.332 |
|
| 2017 |
Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, et al. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T-Cell and NK/T-Cell Lymphomas: an International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28797780 DOI: 10.1016/J.Bbmt.2017.07.027 |
0.439 |
|
| 2017 |
Foss FM, Girardi M. Mycosis Fungoides and Sezary Syndrome. Hematology/Oncology Clinics of North America. 31: 297-315. PMID 28340880 DOI: 10.1016/J.Hoc.2016.11.008 |
0.379 |
|
| 2017 |
Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, ... ... Foss FM, et al. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clinical Lymphoma, Myeloma & Leukemia. PMID 28209473 DOI: 10.1016/J.Clml.2016.10.001 |
0.424 |
|
| 2017 |
Foss FM, Querfeld C, Porcu P, Kim YH, Pacheco T, Halwani AS, DeSimone J, William BM, Seto AG, Ruckman J, Landry ML, Jackson AL, Pestano LA, Dickinson BA, Sanseverino M, et al. Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL). Journal of Clinical Oncology. 35: 7564-7564. DOI: 10.1200/Jco.2017.35.15_Suppl.7564 |
0.416 |
|
| 2017 |
Querfeld C, Foss FM, Pinter-Brown LC, Porcu P, William BM, Pacheco T, Haverkos BM, Kim YH, Guitart J, Halwani AS, DeSimone J, Seto AG, Pestano LA, Jackson AL, Williams PJ, et al. Phase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microRNA-155, in CTCL Patients Blood. 130: 820-820. DOI: 10.1182/Blood.V130.Suppl_1.820.820 |
0.332 |
|
| 2017 |
Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman TA, et al. The Role of Upfront Hematopoietic Stem Cell Transplantation (HSCT) in Peripheral T-Cell Lymphoma (PTCL) Patients in Complete Remission (CR) with a Special Focus on Nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective Multicenter Cohort Study Blood. 130: 342-342. DOI: 10.1182/Blood.V130.Suppl_1.342.342 |
0.38 |
|
| 2017 |
Witzig TE, Sokol L, Jacobsen E, Advani RH, Foss FM, Mondejar R, Piris MA, Bolognese J, Burrows F, Kessler L, Bracken K, Mishra V, Scholz C, Gualberto A. The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma Blood. 130: 2788-2788. DOI: 10.1182/Blood.V130.Suppl_1.2788.2788 |
0.376 |
|
| 2017 |
Foss FM, Horwitz SM, Bellei M, Manni M, Tarantino V, Shustov AR, Dlouhy I, Cabrera ME, Kim WS, Hitz F, Gabus R, Gutierrez A, Varela SB, Vitolo U, Merli F, et al. Outcome of Patients with Gamma Delta T Cell Lymphomas: Analysis of 1429 Cases Registered in the Prospective T-Cell Project Blood. 130: 1512-1512. DOI: 10.1182/Blood.V130.Suppl_1.1512.1512 |
0.392 |
|
| 2017 |
Querfeld C, Foss F, Porcu P, Kim Y, Pacheco T, Haverkos B, Halwani A, DeSimone J, William B, Pinter-Brown L, Seto A, Ruckman J, Landry M, Jackson A, Dickinson B, et al. PH 1 TRIAL EVALUATING MRG-106, A MICRORNA-155 INHIBITOR, ADMINISTERED BY INTRATUMORAL, SUBCUTANEOUS, OR INTRAVENOUS DELIVERY IN CUTANEOUS T-CELL LYMPHOMA (CTCL) PATIENTS Hematological Oncology. 35: 275-276. DOI: 10.1002/Hon.2438_149 |
0.405 |
|
| 2016 |
Foss F, Pro B, Miles Prince H, Sokol L, Caballero D, Horwitz S, Coiffier B. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Medicine. PMID 27981793 DOI: 10.1002/Cam4.939 |
0.439 |
|
| 2016 |
Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, ... ... Foss FM, et al. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer. PMID 27911989 DOI: 10.1002/Cncr.30416 |
0.432 |
|
| 2016 |
Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clinical Lymphoma, Myeloma & Leukemia. 16: 637-643. PMID 27637428 DOI: 10.1016/J.Clml.2016.08.009 |
0.398 |
|
| 2016 |
Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematological Oncology. PMID 27402335 DOI: 10.1002/Hon.2320 |
0.458 |
|
| 2016 |
Cooper DL, Medoff E, Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y. Autologous Stem Cell Mobilization in the Age of Plerixafor. Clinical Lymphoma, Myeloma & Leukemia. PMID 27245311 DOI: 10.1016/J.Clml.2016.04.007 |
0.324 |
|
| 2016 |
Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. Journal of Hematology & Oncology. 9: 22. PMID 26965915 DOI: 10.1186/S13045-016-0243-8 |
0.456 |
|
| 2016 |
Gibson JF, Huang J, Liu KJ, Carlson KR, Foss F, Choi J, Edelson R, Hussong JW, Mohl R, Hill S, Girardi M. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction. Journal of the American Academy of Dermatology. PMID 26874819 DOI: 10.1016/J.Jaad.2015.12.018 |
0.418 |
|
| 2016 |
Foss FM, Parker TL, Li A. Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate. Journal of Clinical Oncology. 34: 7558-7558. DOI: 10.1200/Jco.2016.34.15_Suppl.7558 |
0.412 |
|
| 2016 |
Bellei M, Foss FM, Horwitz SM, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce E, Ko YH, Martinez V, Montoto S, Chiattone C, Moskowitz AJ, et al. The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project Blood. 128: 921-921. DOI: 10.1182/Blood.V128.22.921.921 |
0.449 |
|
| 2016 |
Lansigan F, Horwitz SM, Pinter-Brown LC, Carson KR, Shustov AR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Foss FM. Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study Blood. 128: 4150-4150. DOI: 10.1182/Blood.V128.22.4150.4150 |
0.444 |
|
| 2016 |
Meeks MW, Park HS, Yu JB, Roberts KB, Foss F, Wilson LD. A Novel Prognostic Index for Ocular Adnexal Lymphoma Blood. 128: 3597-3597. DOI: 10.1182/Blood.V128.22.3597.3597 |
0.332 |
|
| 2016 |
Querfeld C, Pacheco T, Foss FM, Halwani AS, Porcu P, Seto AG, Ruckman J, Landry ML, Jackson AL, Pestano LA, Dickinson BA, Sanseverino M, Rodman DM, Gordon G, Marshall W. Preliminary Results of a Phase 1 Trial Evaluating MRG-106, a Synthetic microRNA Antagonist (LNA antimiR) of microRNA-155, in Patients with CTCL Blood. 128: 1829-1829. DOI: 10.1182/Blood.V128.22.1829.1829 |
0.397 |
|
| 2016 |
Khodadoust M, Rook AH, Porcu P, Foss FM, Moskowitz AJ, Shustov AR, Shanbhag S, Sokol L, Shine R, Fling SP, Li S, Rabhar Z, Kim J, Yang Y, Yearley J, et al. Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study Blood. 128: 181-181. DOI: 10.1182/Blood.V128.22.181.181 |
0.381 |
|
| 2015 |
Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, M Vose J. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. British Journal of Haematology. PMID 26627450 DOI: 10.1111/Bjh.13855 |
0.483 |
|
| 2015 |
Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplantation. PMID 26479982 DOI: 10.1038/Bmt.2015.247 |
0.383 |
|
| 2015 |
Bellei M, Nabhan C, Pesce EA, Conte L, Vose JM, Foss F, Federico M. The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project. Current Hematologic Malignancy Reports. PMID 26449717 DOI: 10.1007/S11899-015-0291-0 |
0.431 |
|
| 2015 |
Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, ... ... Foss FM, et al. Genomic landscape of cutaneous T cell lymphoma. Nature Genetics. PMID 26192916 DOI: 10.1038/Ng.3356 |
0.371 |
|
| 2015 |
O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, et al. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26101246 DOI: 10.1200/Jco.2014.59.2782 |
0.465 |
|
| 2015 |
Gibson JF, Alpdogan O, Subtil A, Girardi M, Wilson LD, Roberts K, Foss F. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma. Journal of the American Academy of Dermatology. 72: 1010-5.e5. PMID 25981001 DOI: 10.1016/J.Jaad.2015.01.003 |
0.459 |
|
| 2015 |
Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 100: 794-800. PMID 25795722 DOI: 10.3324/Haematol.2015.123711 |
0.476 |
|
| 2015 |
Gibson JF, Kapur L, Sokhn J, Xu M, Foss FM. A fatal case of primary cutaneous gamma-delta T-cell lymphoma complicated by HLH and cardiac amyloidosis. Clinical Case Reports. 3: 34-8. PMID 25678971 DOI: 10.1002/Ccr3.142 |
0.376 |
|
| 2015 |
Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 774-9. PMID 25605745 DOI: 10.1093/Annonc/Mdv010 |
0.357 |
|
| 2015 |
Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 125: 1883-9. PMID 25605368 DOI: 10.1182/Blood-2014-09-600924 |
0.44 |
|
| 2015 |
Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. British Journal of Haematology. 168: 811-9. PMID 25404094 DOI: 10.1111/Bjh.13222 |
0.465 |
|
| 2015 |
James E, Sokhn JG, Gibson JF, Carlson K, Subtil A, Girardi M, Wilson LD, Foss F. CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature. Leukemia & Lymphoma. 56: 951-7. PMID 24996443 DOI: 10.3109/10428194.2014.938331 |
0.356 |
|
| 2015 |
Federico M, Bellei M, Luminari S, Horwitz SM, Montoto S, Zucca E, Pileri SA, Ko Y, Zinzani PL, Connors JM, Foss FM, Polliack A, Cabrera ME, Kim WS, Spina M, et al. CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project. Journal of Clinical Oncology. 33: 8552-8552. DOI: 10.1200/Jco.2015.33.15_Suppl.8552 |
0.366 |
|
| 2015 |
Douglas M, Allen K, Sweeney J, O'Brien SM, Flinn I, Horwitz SM, Byrd JC, Patel MR, Kahl BS, Foss FM, Porcu P, Kelly V, Stern H. Serum chemokines and cytokines in CLL patients treated with duvelisib, a PI3K-δ,γ inhibitor. Journal of Clinical Oncology. 33: 7072-7072. DOI: 10.1200/Jco.2015.33.15_Suppl.7072 |
0.393 |
|
| 2015 |
O'Connor OA, Özcan M, Jacobsen ED, Roncero Vidal JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, d'Amore FA, Foss F, Kim W, Leonard JP, Chiattone CS, Zinzani PL, et al. First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962) Blood. 126: 341-341. DOI: 10.1182/Blood.V126.23.341.341 |
0.366 |
|
| 2015 |
Johnston PB, Cashen AF, Nikolinakos PG, Beaven AW, Barta SK, Bhat G, Song T, Choi MR, Allen LF, de Vos S, Oki Y, Deng C, Foss FM. Safe and Effective Treatment of Patients with Peripheral T-Cell Lymphoma (PTCL) with the Novel HDAC Inhibitor, Belinostat, in Combination with CHOP: Results of the Bel-CHOP Phase 1 Trial Blood. 126: 253-253. DOI: 10.1182/Blood.V126.23.253.253 |
0.497 |
|
| 2014 |
Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomarker Research. 2: 16. PMID 25279222 DOI: 10.1186/2050-7771-2-16 |
0.461 |
|
| 2014 |
Gibson JF, Foss F, Cooper D, Seropian S, Irizarry D, Barbarotta L, Lansigan F. Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma. British Journal of Haematology. 167: 141-4. PMID 24888971 DOI: 10.1111/Bjh.12944 |
0.438 |
|
| 2014 |
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. Journal of Hematology & Oncology. 7: 11. PMID 24456586 DOI: 10.1186/1756-8722-7-11 |
0.465 |
|
| 2014 |
Foss FM, Duvic M, Lerner A, Rook A, Whittaker S, Kim EJ, Kim YH. Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) with tumors and/or folliculotropic involvement. Journal of Clinical Oncology. 32: 8575-8575. DOI: 10.1200/Jco.2014.32.15_Suppl.8575 |
0.374 |
|
| 2014 |
Foss FM, Pro B, Prince HM, Sokol L, Greenwood M, Caballero D, Horwitz SM, Coiffier B. Responses to romidepsin by line of therapy in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). Journal of Clinical Oncology. 32: 8563-8563. DOI: 10.1200/Jco.2014.32.15_Suppl.8563 |
0.426 |
|
| 2014 |
Horwitz SM, Porcu P, Flinn I, Kahl BS, Sweeney J, Stern HM, Douglas M, Allen K, Kelly P, Foss FM. Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, Shows Activity in Patients with Relapsed/Refractory T-Cell Lymphoma Blood. 124: 803-803. DOI: 10.1182/Blood.V124.21.803.803 |
0.476 |
|
| 2014 |
Flinn I, Oki Y, Patel M, Horwitz SM, Foss FM, Sweeney J, Allen K, Douglas M, Steelman L, Dunbar J, Stern HM, Kelly P, Kahl B. a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL Blood. 124: 802-802. DOI: 10.1182/Blood.V124.21.802.802 |
0.405 |
|
| 2014 |
Pinter-Brown L, Foss FM, Carson KR, Horwitz SM, Rosen ST, Pro B, Federico M, Gisselbrecht C, Hsi ED, Shustov AR, Advani R, Feldman T, Lechowicz MJ, Smith S, Tulpule A, et al. Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL) Blood. 124: 4434-4434. DOI: 10.1182/Blood.V124.21.4434.4434 |
0.4 |
|
| 2014 |
O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Sweeney J, Allen K, Faia K, Stern HM, Kelly P, Flinn I. Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Blood. 124: 3334-3334. DOI: 10.1182/Blood.V124.21.3334.3334 |
0.447 |
|
| 2014 |
Duvic M, Kuzel TM, Dang NH, Prince M, Feldman T, Foss FM, Guo M, Ottesen LH, Ooi CE, Kim YH. A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) Blood. 124: 3097-3097. DOI: 10.1182/Blood.V124.21.3097.3097 |
0.37 |
|
| 2014 |
Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B. Romidepsin Induces Durable Responses in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) Blood. 124: 1742-1742. DOI: 10.1182/Blood.V124.21.1742.1742 |
0.457 |
|
| 2013 |
Foss FM. Treatment strategies for peripheral T-cell lymphomas. Best Practice & Research. Clinical Haematology. 26: 43-56. PMID 23768640 DOI: 10.1016/J.Beha.2013.04.005 |
0.442 |
|
| 2013 |
Foss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR, Komrokji R, Pendergrass K, Bolejack V. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leukemia & Lymphoma. 54: 1373-9. PMID 23278639 DOI: 10.3109/10428194.2012.742521 |
0.418 |
|
| 2013 |
Parker T, Barbarotta L, Foss F. Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma. Future Oncology (London, England). 9: 21-9. PMID 23252560 DOI: 10.2217/Fon.12.168 |
0.446 |
|
| 2013 |
Horwitz SM, Flinn I, Patel MR, Younes A, Foss FM, Oki Y, Sweeney J, Allen K, Dunbar J, Kelly PF, Kahl BS. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory lymphoma. Journal of Clinical Oncology. 31: 8518-8518. DOI: 10.1200/Jco.2013.31.15_Suppl.8518 |
0.406 |
|
| 2013 |
O'Connor OA, Masszi T, Savage KJ, Pinter-Brown LC, Foss FM, Popplewell L, Cashen AF, Doorduijn J, Chawla S, Knoblauch P, Zinzani PL, Brown P, Hess G, Van Hoof A, Horwitz SM, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial. Journal of Clinical Oncology. 31: 8507-8507. DOI: 10.1200/Jco.2013.31.15_Suppl.8507 |
0.402 |
|
| 2013 |
Flinn I, Patel M, Kahl BS, Horwitz SM, Foss FM, Oki Y, Porcu P, Sweeney J, Allen K, Faia K, Harris P, Dunbar J, Stern HM, Kelly P, O'Brien S. Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia Blood. 122: 677-677. DOI: 10.1182/Blood.V122.21.677.677 |
0.353 |
|
| 2013 |
Fraser J, Subtil A, Alpdogan O, Seropian S, Cooper DL, Xu M, Foss FM. Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience Blood. 122: 5092-5092. DOI: 10.1182/Blood.V122.21.5092.5092 |
0.499 |
|
| 2013 |
Frankel AE, Woo JH, Mauldin JP, Foss FM, Duvic M, Neville DM. An Update On The Clinical Activity Of Resimmune, a Targeted Therapy Directed To CD3 Receptor, In Patients With Cutaneous T Cell Lymphomas--CTCL Blood. 122: 4381-4381. DOI: 10.1182/Blood.V122.21.4381.4381 |
0.466 |
|
| 2013 |
Fraser J, Lansigan F, Seropian S, Barbarotta L, Foss FM. A Pilot Study Of Sorafenib In Refractory Or Relapsed T-Cell Lymphoma Patients Blood. 122: 4356-4356. DOI: 10.1182/Blood.V122.21.4356.4356 |
0.493 |
|
| 2013 |
Carson KR, Foss FM, Pinter-Brown L, Horwitz SM, Rosen ST, Frcpa, Pro B, Federico M, Gisselbrecht C, Hsi ED. Analysis Of Peripheral T-Cell Lymphoma (PTCL) Subtype By Race and Geography Using The Comprehensive Oncology Measures For Peripheral T-Cell Lymphoma Treatment (COMPLETE) Dataset Blood. 122: 4284-4284. DOI: 10.1182/Blood.V122.21.4284.4284 |
0.369 |
|
| 2013 |
Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza FR, Carson KR, Evens AM, Foss FM, Horwitz SM, Pro B, Pinter-Brown L, Smith SM, Shustov AR, Savage KJ, Vose JM. A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial Blood. 122: 3044-3044. DOI: 10.1182/Blood.V122.21.3044.3044 |
0.402 |
|
| 2012 |
Bellei M, Chiattone CS, Luminari S, Pesce EA, Cabrera ME, de Souza CA, Gabús R, Zoppegno L, Zoppegno L, Milone J, Pavlovsky A, Connors JM, Foss FM, Horwitz SM, Liang R, et al. T-cell lymphomas in South america and europe. Revista Brasileira De Hematologia E Hemoterapia. 34: 42-7. PMID 23049383 DOI: 10.5581/1516-8484.20120013 |
0.457 |
|
| 2012 |
Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Photodermatology, Photoimmunology & Photomedicine. 28: 250-7. PMID 22971190 DOI: 10.1111/J.1600-0781.2012.00689.X |
0.401 |
|
| 2012 |
Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: A subgroup efficacy analysis from the PROPEL study Clinical Lymphoma, Myeloma and Leukemia. 12: 238-243. PMID 22542448 DOI: 10.1016/J.Clml.2012.01.010 |
0.42 |
|
| 2012 |
Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 119: 4115-22. PMID 22394596 DOI: 10.1182/Blood-2011-11-390211 |
0.422 |
|
| 2012 |
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 631-6. PMID 22271479 DOI: 10.1200/Jco.2011.37.4223 |
0.443 |
|
| 2012 |
Aschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N, Zhang Y. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. Journal of Cancer Survivorship : Research and Practice. 6: 102-14. PMID 22113576 DOI: 10.1007/S11764-010-0164-4 |
0.324 |
|
| 2012 |
Hsi ED, Gruver AM, Foss FM, Carson KR, Pinter-Brown L, Horwitz SM, Rosen ST, Pro B, Federico M, Gisselbrecht C. Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry Blood. 120: 4263-4263. DOI: 10.1182/Blood.V120.21.4263.4263 |
0.308 |
|
| 2012 |
Duvic M, Pinter-Brown L, Foss F, Sokol L, Jorgensen J, Ni X, Challagundla P, Goswami M, Dwyer K, Mohamed N, Kim YH. Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4) Blood. 120: 3697-3697. DOI: 10.1182/Blood.V120.21.3697.3697 |
0.349 |
|
| 2012 |
Parker TL, Barbarotta L, Girardi M, Foss FM. Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma Blood. 120: 3660-3660. DOI: 10.1182/Blood.V120.21.3660.3660 |
0.446 |
|
| 2012 |
Coiffier B, Pro B, Prince M, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov AR, Nielsen T, Nichols J, Wolfson J, et al. Romidepsin Induces Durable Responses in Patients with Peripheral T-Cell Lymphoma: GPI-06–0002 Study Update Blood. 120: 3641-3641. DOI: 10.1182/Blood.V120.21.3641.3641 |
0.429 |
|
| 2012 |
Pileri SA, Bellei M, Vose JM, Connors JM, Foss FM, Horwitz SM, Montoto S, Polliack A, Zinzani PL, Zucca E, Ko Y, Federico M. Evaluation of Quality of Biomarker Data Capture by Peripheral Sites in an International, Cooperative Study: Analysis of 104 Cases From the T-Cell Project. Blood. 120: 2650-2650. DOI: 10.1182/Blood.V120.21.2650.2650 |
0.306 |
|
| 2012 |
Foss FM, Carson KR, Pinter-Brown L, Horwitz SM, Rosen ST, Pro B, Federico M, Gisselbrecht C, Hsi ED. Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE): First Detailed Report of Primary Treatment Blood. 120: 1614-1614. DOI: 10.1182/Blood.V120.21.1614.1614 |
0.454 |
|
| 2012 |
Isufi I, Yao X, Seropian S, Cooper D, Shlomchik W, Deng Y, Barbarotta L, Foss F. Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic Malignancies Biology of Blood and Marrow Transplantation. 18: S339. DOI: 10.1016/J.Bbmt.2011.12.356 |
0.321 |
|
| 2011 |
Horwitz SM, Coiffier B, Foss FM, Prince HM, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown LC, Padmanabhan S, Shustov AR, Nichols J, Balser J, et al. Complete responses (CR/CRu) on a phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8033. PMID 28023572 DOI: 10.1200/Jco.2011.29.15_Suppl.8033 |
0.363 |
|
| 2011 |
Foss F. Evolving Therapy of Peripheral T-cell Lymphoma: 2010 and beyond. Therapeutic Advances in Hematology. 2: 161-173. PMID 23556087 DOI: 10.1177/2040620711408491 |
0.455 |
|
| 2011 |
Querfeld C, Rosen ST, Guitart J, Rademaker A, Pezen DS, Dolan ME, Baron J, Yarosh DB, Foss F, Kuzel TM. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with Oâ¶-methylguanine-DNA methyltransferase and mismatch repair proteins. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5748-54. PMID 21747120 DOI: 10.1158/1078-0432.Ccr-11-0556 |
0.394 |
|
| 2011 |
Foss FM. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. Expert Opinion On Drug Metabolism & Toxicology. 7: 1141-52. PMID 21726160 DOI: 10.1517/17425255.2011.595404 |
0.466 |
|
| 2011 |
Foss F, Duvic M, Olsen EA. Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. American Journal of Hematology. 86: 627-630. PMID 21674574 DOI: 10.1002/Ajh.22039 |
0.413 |
|
| 2011 |
Cooper DL, Pratt K, Baker J, Medoff E, Conkling-Walsh A, Foss F, Snyder E, Yen W, Seropian SE. Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution. Clinical Lymphoma, Myeloma & Leukemia. 11: 267-72. PMID 21658654 DOI: 10.1016/J.Clml.2011.03.014 |
0.385 |
|
| 2011 |
Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 117: 6756-67. PMID 21493798 DOI: 10.1182/Blood-2010-05-231548 |
0.412 |
|
| 2011 |
Foss F. Hematology: relapsed and refractory PTCL--into the therapeutic abyss. Nature Reviews Clinical Oncology. 8: 321-322. PMID 21468128 DOI: 10.1038/Nrclinonc.2011.51 |
0.414 |
|
| 2011 |
Foss FM. Molecular predictors of response in aggressive T-cell lymphomas. Cancer Journal (Sudbury, Mass.). 17: 142-8. PMID 21427558 DOI: 10.1097/Ppo.0B013E31821828B7 |
0.405 |
|
| 2011 |
Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, ... Foss F, et al. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). Journal of the American Academy of Dermatology. 64: 352-404. PMID 21145619 DOI: 10.1016/J.Jaad.2010.08.037 |
0.332 |
|
| 2011 |
Coiffier B, Pro B, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov AR, Nichols J, Carroll S, et al. Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma Blood. 118: 591-591. DOI: 10.1182/Blood.V118.21.591.591 |
0.476 |
|
| 2011 |
Zain JM, Foss FM, Diefenbach CS, Petrylak D, Narwal A, Neylon E, Knoblauch P, O'Connor OA. Preliminary Results of An Ongoing Phase I Trial of Oral Belinostat a Novel Histone Deacetylase Inhibitor in Patients with Lymphoid Malignancies, Blood. 118: 3710-3710. DOI: 10.1182/Blood.V118.21.3710.3710 |
0.353 |
|
| 2010 |
Armitage JO, Hsi ED, Foss FM. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness. Clinical Advances in Hematology & Oncology : H&O. 8: 1-15. PMID 21491667 |
0.358 |
|
| 2010 |
Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Management and Research. 2: 53-59. PMID 21188096 DOI: 10.2147/Cmar.S5009 |
0.459 |
|
| 2010 |
Berger C, Hoffmann K, Vasquez JG, Mane S, Lewis J, Filler R, Lin A, Zhao H, Durazzo T, Baird A, Lin W, Foss F, Christensen I, Girardi M, Tigelaar R, et al. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood. 116: 4838-47. PMID 20720185 DOI: 10.1182/Blood-2009-11-256040 |
0.347 |
|
| 2010 |
Foss FM. Enhancing existing approaches to peripheral T-cell lymphoma. Seminars in Hematology. 47: S8-10. PMID 20359584 DOI: 10.1053/J.Seminhematol.2010.01.012 |
0.435 |
|
| 2010 |
Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs. 70: 273-86. PMID 20166766 DOI: 10.2165/11532190-000000000-00000 |
0.47 |
|
| 2010 |
Han X, Zheng T, Foss FM, Ma S, Holford TR, Boyle P, Leaderer B, Zhao P, Dai M, Zhang Y. Alcohol consumption and non-Hodgkin lymphoma survival. Journal of Cancer Survivorship : Research and Practice. 4: 101-9. PMID 20039144 DOI: 10.1007/S11764-009-0111-4 |
0.307 |
|
| 2010 |
Shaughnessy PJ, Bolwell BJ, van Besien K, Mistrik M, Grigg A, Dodds A, Prince HM, Durrant S, Ilhan O, Parenti D, Gallo J, Foss F, Apperley J, Zhang MJ, Horowitz MM, et al. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 45: 1068-76. PMID 19915634 DOI: 10.1038/Bmt.2009.307 |
0.345 |
|
| 2010 |
Lansigan F, Komarovskaya M, Seropian S, Cooper D, Foss FM. A pilot study of sorafenib examining biomarkers in refractory or relapsed T-cell lymphoma patients. Journal of Clinical Oncology. 28: TPS300-TPS300. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps300 |
0.455 |
|
| 2010 |
Foss FM, Sjak-Shie NN, Goy A, Advani R, Jacobsen ED. Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. Journal of Clinical Oncology. 28: 8045-8045. DOI: 10.1200/Jco.2010.28.15_Suppl.8045 |
0.412 |
|
| 2010 |
Duvic M, Pinter-Brown L, Foss FM, Sokol L, Jorgensen J, Spitalny GL, Kim YH. Results of a Phase 1/2 Study for KW-0761, a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4), In CTCL Patients Blood. 116: 962-962. DOI: 10.1182/Blood.V116.21.962.962 |
0.402 |
|
| 2010 |
O'Connor OA, Haouin C, Zinzani PL, Gisselbrecht C, Foss FM, Savage KJ, Pro B, Pinter-Brown L, Bartlett NL, Horwitz SM, Jacobsen ED, Koutsoukos T, Fruchtman SM, Coiffier B. Pralatrexate Reverses the Trend to Progressive Resistance to Successive Systemic Treatment Regimens In Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Blood. 116: 4881-4881. DOI: 10.1182/Blood.V116.21.4881.4881 |
0.399 |
|
| 2010 |
Lansigan F, Seropian S, Cooper DL, Potter V, Sowers N, Foss FM. A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma. Blood. 116: 2816-2816. DOI: 10.1182/Blood.V116.21.2816.2816 |
0.457 |
|
| 2010 |
Horwitz SM, Kim YH, Foss FM, Zain JM, Myskowski P, Lechowicz MJ, Fisher DC, Shustov A, Bartlett NL, Delioukina ML, Koutsoukos T, Fruchtman SM, O'Connor OA, Duvic M. Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study. Blood. 116: 2800-2800. DOI: 10.1182/Blood.V116.21.2800.2800 |
0.404 |
|
| 2010 |
Zain JM, Foss FM, de Bono JS, Narwal A, Neylon E, Blumenschein G, Lassen U, Knoblauch P, Diefenbach CS, O'Connor OA. Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies. Blood. 116: 1787-1787. DOI: 10.1182/Blood.V116.21.1787.1787 |
0.326 |
|
| 2010 |
Foss FM, Horwitz SM, Pinter-Brown L, Goy A, Pro B, Coiffier B, Popplewell L, Savage KJ, Shustov A, Zain JM, Koutsoukos T, Fruchtman SM, O'Connor OA. Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF) Blood. 116: 1762-1762. DOI: 10.1182/Blood.V116.21.1762.1762 |
0.471 |
|
| 2010 |
Isufi I, Barile A, Russell K, Hryniewicz K, Baker J, Medoff E, Jacoby D, Lee F, Foss FM, Cooper DL, Seropian S. Brain Natriuretic Peptide (BNP) Elevations In Allogeneic Stem Cell Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction. Blood. 116: 1309-1309. DOI: 10.1182/Blood.V116.21.1309.1309 |
0.346 |
|
| 2010 |
Coiffier B, Pro B, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, et al. Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy Blood. 116: 114-114. DOI: 10.1182/Blood.V116.21.114.114 |
0.434 |
|
| 2010 |
Karkanitsa P, Weissman S, Rabinovich P, Abken H, Hombach A, Komarovskaya M, Foss FM. Abstract 1936: Anti CD30 chimeric immune receptor mRNA for therapy of CD30+ lymphomas Cancer Research. 70: 1936-1936. DOI: 10.1158/1538-7445.Am10-1936 |
0.325 |
|
| 2009 |
Zain JM, Foss F, Kelly WK, DeBono J, Petrylak D, Narwal A, Neylon E, Blumenschein G, Lassen U, O'Connor OA. Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8580. PMID 27962263 DOI: 10.1200/Jco.2009.27.15_Suppl.8580 |
0.361 |
|
| 2009 |
Lansigan F, Cooper D, Seropian S, Foss F. Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8558. PMID 27960993 DOI: 10.1200/Jco.2009.27.15_Suppl.8558 |
0.427 |
|
| 2009 |
Duvic M, Forero-Torres A, Foss F, Olsen E, Pinter-Brown L, Kim Y. Long-term treatment of CTCL with the oral PNP inhibitor, forodesine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8552. PMID 27960987 DOI: 10.1200/Jco.2009.27.15_Suppl.8552 |
0.324 |
|
| 2009 |
Foss F, Besien Kv. Reduced-intensity and nonmyeloablative conditioning regimens. Cancer Treatment and Research. 144: 209-232. PMID 19779868 DOI: 10.1007/978-0-387-78580-6_9 |
0.355 |
|
| 2009 |
Federico M, Bellei M, Pesce E, Zucca E, Pileri S, Montoto S, Weisenburger DD, Ruediger T, Ko. YH, Liang R, Zinzani PL, Connors JM, Foss FM, Horwitz SM, Polliack A, et al. T-Cell Project: an international, longitudinal, observational study of patients with aggressive peripheral T-cell lymphoma Revista Brasileira De Hematologia E Hemoterapia. 31. DOI: 10.1590/S1516-84842009000800007 |
0.423 |
|
| 2009 |
Pohlman B, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Ben-Yehuda D, beylot-Barry M, Hillen U, Fagerberg J, Foss FM. Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma. Blood. 114: 920-920. DOI: 10.1182/Blood.V114.22.920.920 |
0.426 |
|
| 2009 |
Cooper DL, Baker J, Medoff E, Pratt K, Conkling-Walsh A, Snyder EL, Seropian S, Foss F. Stem Cell Mobilization Using 5 Pm Dosing of Plerixafor. Blood. 114: 4233-4233. DOI: 10.1182/Blood.V114.22.4233.4233 |
0.343 |
|
| 2009 |
Foss F, Duvic M, Olsen EA, Kozlovski A. Complete Responses with Denileukin Diftitox in Cutaneous T-Cell Lymphoma Studies. Blood. 114: 3745-3745. DOI: 10.1182/Blood.V114.22.3745.3745 |
0.377 |
|
| 2009 |
Duvic M, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Rizvi S, Chen C, Arduino JM, Olsen EA. The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden. Blood. 114: 1709-1709. DOI: 10.1182/Blood.V114.22.1709.1709 |
0.331 |
|
| 2008 |
Lansigan F, Choi J, Foss FM. Cutaneous T-cell lymphoma. Hematology/Oncology Clinics of North America. 22: 979-96, x. PMID 18954747 DOI: 10.1016/J.Hoc.2008.07.014 |
0.403 |
|
| 2008 |
Choi J, Foss F. Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia. The Yale Journal of Biology and Medicine. 79: 169-72. PMID 17940627 |
0.338 |
|
| 2008 |
Alpdogan O, Lenox R, Barile A, Foss F, Shlomchik W, Reuben C, Cooper D, Seropian S. Should All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Remission? Blood. 112: 4396-4396. DOI: 10.1182/Blood.V112.11.4396.4396 |
0.391 |
|
| 2008 |
Lansigan F, Seropian S, Cooper D, Foss F. A Retrospective Comparison of Autologous Vs. Allogeneic Transplantation for Peripheral T-Cell Lymphoma: A Single Institution Experience Blood. 112: 4392-4392. DOI: 10.1182/Blood.V112.11.4392.4392 |
0.435 |
|
| 2008 |
Alpdogan O, Ornstein D, Subtil T, Seropian S, Cooper DL, Foss F. Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL) Blood. 112: 3750-3750. DOI: 10.1182/Blood.V112.11.3750.3750 |
0.487 |
|
| 2008 |
Maggiore RJ, Cooper DL, Foss FM, Shlomchik WD, Seropian SE. Sirolimus-Containing Graft-Versus-Host Disease Prophylaxis and High- Resolution HLA Typing Improves the Outcome of Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 112: 2216-2216. DOI: 10.1182/Blood.V112.11.2216.2216 |
0.352 |
|
| 2007 |
Choi J, Foss F. Cutaneous T-cell lymphoma: Biologic targets for therapy Current Hematologic Malignancy Reports. 2: 272-277. PMID 20425380 DOI: 10.1007/S11899-007-0037-8 |
0.426 |
|
| 2007 |
Duvic M, Foss FM. Mycosis fungoides: pathophysiology and emerging therapies. Seminars in Oncology. 34: S21-8. PMID 18086343 DOI: 10.1053/J.Seminoncol.2007.11.006 |
0.419 |
|
| 2007 |
Hathaway T, Subtil A, Kuo P, Foss F. Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 7: 541-545. PMID 18021473 DOI: 10.3816/Clm.2007.N.040 |
0.464 |
|
| 2007 |
Kuzel TM, Li S, Eklund J, Foss F, Gascoyne R, Abramson N, Schwerkoske JF, Weller E, Horning SJ. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497. Leukemia & Lymphoma. 48: 2397-402. PMID 17943599 DOI: 10.1080/10428190701694186 |
0.414 |
|
| 2007 |
Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3109-15. PMID 17577020 DOI: 10.1200/Jco.2006.10.2434 |
0.442 |
|
| 2007 |
Querfeld C, Rosen ST, Guitart J, Rademaker A, Foss F, Gupta R, Kuzel TM. Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome. Journal of the American Academy of Dermatology. 56: 580-3. PMID 17367611 DOI: 10.1016/J.Jaad.2006.08.067 |
0.441 |
|
| 2007 |
Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treatment Reviews. 33: 146-60. PMID 17275192 DOI: 10.1016/J.Ctrv.2006.08.006 |
0.473 |
|
| 2007 |
Foss F, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith M, Komrokji R, Pendergrass K, Bolejack V, Watts K, Acosta M. Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial. Blood. 110: 3449-3449. DOI: 10.1182/Blood.V110.11.3449.3449 |
0.487 |
|
| 2007 |
Geskin L, Foss F, Duvic M, Straus D, Horwitz S, Zain J, Kuzel T, Querfeld C, Campbell K, Knobler R. Efficacy of Extracorporeal Photopheresis (ECP) Monotherapy in the Treatment of Cutaneous T Cell Lymphoma. Blood. 110: 2561-2561. DOI: 10.1182/Blood.V110.11.2561.2561 |
0.384 |
|
| 2007 |
Duvic M, Forero-Torres A, Foss F, Olsen E, Kim Y. Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study. Blood. 110: 122-122. DOI: 10.1182/Blood.V110.11.122.122 |
0.378 |
|
| 2006 |
Olsen E, Kim YH, Kuzel T, Pacheco TR, Foss F, Parker S, Wang JG, Frankel SR, Lis J, Duvic M. Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIb trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 7500. PMID 27955340 DOI: 10.1200/Jco.2006.24.18_Suppl.7500 |
0.376 |
|
| 2006 |
Chin KM, Foss FM. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox. Clinical Lymphoma & Myeloma. 7: 199-204. PMID 17229335 DOI: 10.3816/Clm.2006.N.059 |
0.43 |
|
| 2006 |
Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, Laliberté RJ, Ryan JL, Zonno K, Rook AH. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. Journal of the American Academy of Dermatology. 55: 807-13. PMID 17052486 DOI: 10.1016/J.Jaad.2006.06.038 |
0.454 |
|
| 2006 |
Foss FM. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation. Seminars in Hematology. 43: S35-43. PMID 16549113 DOI: 10.1053/J.Seminhematol.2005.12.007 |
0.385 |
|
| 2006 |
Dummer R, Foss F, Dreno B, Bagot M. Clinical Experience: Practical Management of Five Patients With Cutaneous T-Cell Lymphoma (CTCL)-Related Symptoms Seminars in Oncology. 33: 26-32. PMID 16516673 DOI: 10.1053/J.Seminoncol.2005.12.020 |
0.426 |
|
| 2006 |
Foss F. Immunomodulatory Effects of Rexinoids Seminars in Oncology. 33: 21-25. PMID 16516672 DOI: 10.1053/J.Seminoncol.2005.12.019 |
0.384 |
|
| 2006 |
Foss F. Clinical experience with denileukin diftitox (ONTAK). Seminars in Oncology. 33: 11-16. PMID 16516670 DOI: 10.1053/J.Seminoncol.2005.12.017 |
0.386 |
|
| 2006 |
Duvic M, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Randolph S, Richon VM, Olsen EA. Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial. Blood. 108: 399-399. DOI: 10.1182/Blood.V108.11.399.399 |
0.377 |
|
| 2006 |
Casale DA, Bartlett NL, Hurd DD, Foss F, Pro B, Sokol L, Lieberman R, Luz H. A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia. Blood. 108: 2727-2727. DOI: 10.1182/Blood.V108.11.2727.2727 |
0.426 |
|
| 2006 |
Forero-Torres A, Bernstein SH, Gopal A, Foss F, Leonard JP, Rosenblatt JD, Bartlett NL, Cheson BD, Epner E, Hernandez-Ilizaliturri FJ, Proctor SJ, Brice P, Tilly H, Haioun C, Jerkeman M, et al. SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL). Blood. 108: 2718-2718. DOI: 10.1182/Blood.V108.11.2718.2718 |
0.436 |
|
| 2006 |
Foss F, Duvic M, Geskin L, Anderson J, Porcu P, Hohl RJ, Cooper M, Zain JM, Zic J, Hibberd P, Acosta M. Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status. Blood. 108: 2712-2712. DOI: 10.1182/Blood.V108.11.2712.2712 |
0.327 |
|
| 2006 |
Duvic M, Forero-Torres A, Foss F, Olsen EA, Kim Y. Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study. Blood. 108: 2467-2467. DOI: 10.1182/Blood.V108.11.2467.2467 |
0.414 |
|
| 2006 |
Foss FM, Sjak-Shie N, Goy A, Advani R, Jacobsen E, Acosta M. A Phase II Study of Denileukin Diftitox (Ontak®) with CHOP Chemotherapy in Patients with Newly-Diagnosed Aggressive T-Cell Lymphomas, the CONCEPT Trial: Interim Analysis. Blood. 108: 2461-2461. DOI: 10.1182/Blood.V108.11.2461.2461 |
0.481 |
|
| 2006 |
Foss F, Vose JM, Neumann M, Harris ME. Purine analogues in the treatment of lymphoid malignancies Seminars in Hematology. 43. DOI: 10.1053/J.Seminhematol.2005.12.014 |
0.446 |
|
| 2005 |
Huang Z, Higgins B, Foss F. Activity of gallium nitrate in refractory peripheral T-cell lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 6: 43-45. PMID 15989706 DOI: 10.3816/Clm.2005.N.026 |
0.458 |
|
| 2005 |
Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A, Chan G, Stiffler K, Miller KB. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplantation. 35: 1187-93. PMID 15852025 DOI: 10.1038/Sj.Bmt.1704984 |
0.391 |
|
| 2005 |
Foss F, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 106: 454-457. PMID 15811959 DOI: 10.1182/Blood-2004-11-4570 |
0.435 |
|
| 2005 |
Eklund JW, Weller E, Kuzel TM, Foss F, Gascoyne R, Abramson N, Schwerkoske JF, Horning S. Phase II study of denileukin diftitox for previously treated low grade non-Hodgkin’s lymphoma: E1497 final report Journal of Clinical Oncology. 23: 6684-6684. DOI: 10.1200/Jco.2005.23.16_Suppl.6684 |
0.399 |
|
| 2005 |
Pal SE, Winer ES, Higgins B, Dungy A, Foss F. Response to tositumamab and 131 I-tositumomab in follicular lymphoma based on the Follicular Lymphoma International Prognostic Index (FLIPI) Journal of Clinical Oncology. 23: 6629-6629. DOI: 10.1200/Jco.2005.23.16_Suppl.6629 |
0.33 |
|
| 2005 |
Forero A, Bernstein S, Gopal A, Foss F, Leonard J, Bartlett N, Cheson B, Barton J. Initial phase II results of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL) Journal of Clinical Oncology. 23: 6601-6601. DOI: 10.1200/Jco.2005.23.16_Suppl.6601 |
0.393 |
|
| 2005 |
Levesque A, Savard A, Roy D, Foss F, Scotto C. Control of Cell Death Levels Using Th9402-Based PDT Treatment on Fresh PBMC, and Potential Application to Patients with cGvHD. Blood. 106: 5258-5258. DOI: 10.1182/Blood.V106.11.5258.5258 |
0.363 |
|
| 2005 |
Duvic M, Kunishige J, Kim YH, Foreno-Torres A, Pinter-Brown LC, Rarick MU, Zic J, Worobec SM, Foss F, Flessland K, Barton J. Preliminary Phase II Results of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Cutaneous Anaplastic Large Cell Lymphoma (ALCL). Blood. 106: 4802-4802. DOI: 10.1182/Blood.V106.11.4802.4802 |
0.397 |
|
| 2005 |
Chan G, Klein A, Sprague K, Miller K, Foss F. Grade 2–4 acute graft-versus-host disease and extensive chronic graft versus host disease are associated with significantly decreased survival following reduced intensity allogeneic stem cell transplantation Biology of Blood and Marrow Transplantation. 11: 51. DOI: 10.1182/Blood.V104.11.1246.1246 |
0.377 |
|
| 2005 |
Abhyankar S, Shaughnessy P, Bolwell B, van Besien K, Mistrik M, Grigg A, Dodds A, Prince H, Machado A, Thienel U, Wang J, Foss F, Apperley J. A multi-institutional study of extracorporeal photoimmune therapy (ECP) with UVADEX® for the prevention of acute GVHD in patients (pts) undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation (AHCT) Biology of Blood and Marrow Transplantation. 11: 37. DOI: 10.1016/J.Bbmt.2004.12.107 |
0.357 |
|
| 2004 |
Ji Y, Foss F. Combination therapy with pentostatin and cyclophosphamide for advanced refractory cutaneous T cell lymphoma (CTCL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 6713. PMID 28014705 DOI: 10.1200/jco.2004.22.14_suppl.6713 |
0.34 |
|
| 2004 |
Rao RA, Chin K, Pilichowska M, Foss F. Outcomes in peripheral T-cell lymphoma: Prognosis based on IPI staging. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 6706. PMID 28014609 DOI: 10.1200/jco.2004.22.14_suppl.6706 |
0.301 |
|
| 2004 |
Duvic M, Ziari S, Olsen EA, Foss FM. Phase 1-2 multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 6733. PMID 28014492 DOI: 10.1200/Jco.2004.22.14_Suppl.6733 |
0.445 |
|
| 2004 |
Foss FM. Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. Best Practice & Research. Clinical Haematology. 17: 573-84. PMID 15494295 DOI: 10.1016/J.Beha.2004.08.009 |
0.342 |
|
| 2004 |
Foss F. Mycosis fungoides and the Sézary syndrome. Current Opinion in Oncology. 16: 421-428. PMID 15314509 DOI: 10.1097/00001622-200409000-00002 |
0.402 |
|
| 2004 |
Miller KB, Roberts TF, Chan G, Schenkein DP, Lawrence D, Sprague K, Gorgun G, Relias V, Grodman H, Mahajan A, Foss FM. A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplantation. 33: 881-9. PMID 14990986 DOI: 10.1038/Sj.Bmt.1704454 |
0.373 |
|
| 2004 |
Levesque A, Savard A, Roy D, Foss F, Scotto C. Potential TH9402-Based ECP Treatment for cGvHD Patients. Blood. 104: 5119-5119. DOI: 10.1182/Blood.V104.11.5119.5119 |
0.448 |
|
| 2004 |
Rao R, Chin K, Chan G, Sprague K, Klein A, Miller KB, Foss F, Snydman DR. Cytomegalovirus Reactivation and Relapse Following Allogeneic Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen. Blood. 104: 5104-5104. DOI: 10.1182/Blood.V104.11.5104.5104 |
0.396 |
|
| 2004 |
Pal SE, Winer ES, Chin K, Dungy A, Higgins B, Foss F. Response to Tositumomab and Iodine 131I-Tositumomab (BEXXAR) Based on International Prognostic Index (IPI) Score. Blood. 104: 4630-4630. DOI: 10.1182/Blood.V104.11.4630.4630 |
0.411 |
|
| 2004 |
Foss FM, Higgins B. Intermediate-Dose Interleukin-2 Demonstrates Activity in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma. Blood. 104: 2642-2642. DOI: 10.1182/Blood.V104.11.2642.2642 |
0.481 |
|
| 2004 |
Forero-Torres A, Bernstein SH, Gopal AK, Foss F, Leonard JP, Rosenblatt JD, Bartlett NL, Cheson BD, Epner E, Hernandez-Illizaliturri FJ, Proctor SJ, Brice P, Tilly H, Haioun C, Jerkeman M, et al. SGN-30 (Anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL) Blood. 106: 2637-2637. DOI: 10.1182/Blood.V104.11.2637.2637 |
0.451 |
|
| 2004 |
Leonard JP, Rosenblatt JD, Bartlett NL, Gopal A, Younes A, Fisher D, Foss F, Forero A, Bernstein S, Cheson B, Carabasi MH, Bociek RG, Hart B, McDonald M. Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin’s Disease. Blood. 104: 2635-2635. DOI: 10.1182/Blood.V104.11.2635.2635 |
0.417 |
|
| 2004 |
Shaughnessy PJ, Bolwell BJ, Abhyankar S, van Besien K, Mistrik M, Grigg A, Dodds A, Prince HM, Machado A, Thienel U, Wang J, Foss F, Apperley J. A Multi-Institutional Study of Extracorporeal Photoimmune Therapy with UVADEX® for the Prevention of Acute GVHD in Patients Undergoing Standard Myeloablative Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 104: 1230-1230. DOI: 10.1182/Blood.V104.11.1230.1230 |
0.357 |
|
| 2003 |
Foss F. Overview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic Approaches Leukemia & Lymphoma. 44. PMID 15202526 DOI: 10.1080/10428190310001623757 |
0.461 |
|
| 2003 |
DiVenuti G, Nawgiri R, Foss F. Denileukin Diftitox and Hyper-CVAD in the Treatment Human T-Cell Lymphotropic Virus 1–Associated Adult T-Cell Leukemia/Lymphoma Clinical Lymphoma, Myeloma & Leukemia. 4: 176-178. PMID 14715100 DOI: 10.3816/Clm.2003.N.027 |
0.44 |
|
| 2003 |
Kuzel TM, Junghans R, Foss FM. Novel agents for cutaneous T-cell lymphoma. Hematology/Oncology Clinics of North America. 17: 1459-66, x. PMID 14710896 DOI: 10.1016/S0889-8588(03)00112-6 |
0.454 |
|
| 2003 |
Foss FM, Waldmann TA. Interleukin-2 receptor-directed therapies for cutaneous lymphomas. Hematology/Oncology Clinics of North America. 17: 1449-58. PMID 14710895 DOI: 10.1016/S0889-8588(03)00110-2 |
0.395 |
|
| 2003 |
Dearden CE, Foss FM. Peripheral T-cell lymphomas: diagnosis and management. Hematology/Oncology Clinics of North America. 17: 1351-66. PMID 14710889 DOI: 10.1016/S0889-8588(03)00119-9 |
0.476 |
|
| 2003 |
Chan GW, Foss FM, Klein AK, Sprague K, Miller KB. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 9: 753-9. PMID 14677114 DOI: 10.1016/J.Bbmt.2003.08.002 |
0.358 |
|
| 2003 |
Foss FM. Extracorporeal photopheresis in the treatment of graft-vs-host disease. Journal of Cutaneous Medicine and Surgery. 7: 13-7. PMID 12958702 DOI: 10.1007/S10227-003-5003-Z |
0.393 |
|
| 2003 |
Chan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 9: 170-6. PMID 12652467 DOI: 10.1016/S1083-8791(03)70006-8 |
0.339 |
|
| 2002 |
Connors JM, Hsi ED, Foss FM. Lymphoma of the skin Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 263-282. PMID 12446427 DOI: 10.1182/Asheducation-2002.1.263 |
0.398 |
|
| 2002 |
Shao RH, Tian X, Gorgun G, Urbano AG, Foss FM. Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene. Leukemia Research. 26: 1077-83. PMID 12443879 DOI: 10.1016/S0145-2126(02)00059-0 |
0.762 |
|
| 2002 |
Görgün G, Spek Jvd, Cosenza L, Menevse A, Foss F. Altered biological activity associated with C-terminal modifications of IL-7. Cytokine. 20: 17-22. PMID 12441142 DOI: 10.1006/Cyto.2002.1974 |
0.311 |
|
| 2002 |
French LE, Alcindor T, Shapiro M, McGinnis KS, Margolis DJ, Porter D, Leonard DG, Rook AH, Foss F. Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis. Bone Marrow Transplantation. 30: 509-15. PMID 12379890 DOI: 10.1038/Sj.Bmt.1703705 |
0.439 |
|
| 2002 |
Frankel AE, Rossi P, Kuzel TM, Foss F. Diphtheria fusion protein therapy of chemoresistant malignancies. Current Cancer Drug Targets. 2: 19-36. PMID 12188918 DOI: 10.2174/1568009023333944 |
0.355 |
|
| 2002 |
Gorgun G, Foss FM. Immunomodulatory effects of RXR rexinoids : Modulation of high affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood. 100: 1399-1403. PMID 12149223 DOI: 10.1182/Blood-2002-01-0300 |
0.41 |
|
| 2002 |
Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood. 100: 941-7. PMID 12130506 DOI: 10.1182/Blood-2002-01-0068 |
0.383 |
|
| 2002 |
Foss FM. Immunologic mechanisms of antitumor activity. Seminars in Oncology. 29: 5-11. PMID 12068382 DOI: 10.1053/Sonc.2002.33076 |
0.313 |
|
| 2002 |
Bailey HH, Levy D, Harris LS, Schink JC, Foss F, Beatty P, Wadler S. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecologic Oncology. 85: 464-8. PMID 12051875 DOI: 10.1006/Gyno.2002.6647 |
0.331 |
|
| 2002 |
Foss FM, Gorgun G, Miller KB. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplantation. 29: 719-25. PMID 12040467 DOI: 10.1038/Sj.Bmt.1703529 |
0.395 |
|
| 2002 |
Urbano A, Gorgun G, Foss F. Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells Biochemical Pharmacology. 63: 689-692. PMID 11992636 DOI: 10.1016/S0006-2952(01)00916-9 |
0.752 |
|
| 2002 |
Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma. 2: 222-8. PMID 11970761 DOI: 10.3816/Clm.2002.N.003 |
0.392 |
|
| 2002 |
Cosenza L, Gorgun G, Urbano A, Foss F. Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cellular Signalling. 14: 317-325. PMID 11858939 DOI: 10.1016/S0898-6568(01)00245-5 |
0.758 |
|
| 2002 |
Foss FM. An oncologist's approach to therapy for cutaneous T-cell lymphoma. Clinical Lymphoma. S9-14. PMID 11707857 DOI: 10.3816/Clm.2000.S.002 |
0.456 |
|
| 2002 |
Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clinical Lymphoma. 1: 298-302. PMID 11707845 DOI: 10.3816/Clm.2001.N.005 |
0.428 |
|
| 2002 |
Foss FM. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clinical Lymphoma. 1: 110-6; discussion 11. PMID 11707818 DOI: 10.3816/Clm.2000.N.009 |
0.368 |
|
| 2001 |
Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, Foss F, Shapiro M, Kuzel TM, Olsen EA, Vonderheid EC, Laliberte R, Sherman ML. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Annals of the New York Academy of Sciences. 941: 177-84. PMID 11594571 DOI: 10.1111/J.1749-6632.2001.Tb03721.X |
0.43 |
|
| 2001 |
Foss FM. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. Annals of the New York Academy of Sciences. 941: 166-76. PMID 11594570 DOI: 10.1111/J.1749-6632.2001.Tb03720.X |
0.427 |
|
| 2001 |
Argiris A, Heald P, Kuzel T, Foss FM, DiStasio S, Cooper DL, Arbuck S, Murren JR. Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma. Investigational New Drugs. 19: 321-6. PMID 11561692 DOI: 10.1023/A:1010613912335 |
0.451 |
|
| 2001 |
Alcindor T, Gorgun G, Miller KB, Roberts TF, Sprague K, Schenkein DP, Foss FM. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood. 98: 1622-5. PMID 11520818 DOI: 10.1182/Blood.V98.5.1622 |
0.373 |
|
| 2001 |
Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, ... Foss F, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 376-88. PMID 11208829 DOI: 10.1200/Jco.2001.19.2.376 |
0.41 |
|
| 1999 |
Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma Cancer. 86: 1368-1376. PMID 10506727 DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8 |
0.333 |
|
| 1999 |
Foss FM, Kuzel TM. Novel treatment approaches for cutaneous T-cell lymphoma. Cancer Treatment and Research. 99: 227-40. PMID 9891869 DOI: 10.1007/978-0-585-38571-6_9 |
0.391 |
|
| 1998 |
Urbano A, McCaffrey R, Foss F. Isolation and characterization of NUC70, a cytoplasmic hematopoietic apoptotic endonuclease Journal of Biological Chemistry. 273: 34820-34827. PMID 9857008 DOI: 10.1074/Jbc.273.52.34820 |
0.75 |
|
| 1998 |
Saleh MN, LeMaistre CF, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Sams MW, Nichols JC. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides Journal of the American Academy of Dermatology. 39: 63-73. PMID 9674399 DOI: 10.1016/S0190-9622(98)70403-7 |
0.455 |
|
| 1998 |
Sweeney EB, Foss FM, Murphy JR, vanderSpek JC. Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: a novel agent for the elimination of IL-7 receptor positive cells. Bioconjugate Chemistry. 9: 201-7. PMID 9548535 DOI: 10.1021/Bc9701757 |
0.326 |
|
| 1998 |
LeMaistre CF, Saleh MN, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Nichols JC. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interkeukin-2 Blood. 91: 399-405. DOI: 10.1182/Blood.V91.2.399.399_399_405 |
0.445 |
|
| 1997 |
Nichols J, Foss F, Kuzel TM, LeMaistre CF, Platanias L, Ratain MJ, Rook A, Saleh M, Schwartz G. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. European Journal of Cancer (Oxford, England : 1990). S34-6. PMID 9166099 DOI: 10.1016/S0959-8049(96)00327-9 |
0.463 |
|
| 1997 |
Demierre MF, Foss FM, Koh HK. Proceedings of the International Consensus Conference on Cutaneous T- Cell Lymphoma (CTCL) Treatment Recommendations Journal of the American Academy of Dermatology. 36: 460-466. PMID 9091480 DOI: 10.1016/S0190-9622(97)80226-5 |
0.398 |
|
| 1996 |
Bunn PA, Foss FM. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). Journal of Cellular Biochemistry. Supplement. 24: 12-23. PMID 8806090 DOI: 10.1002/Jcb.240630503 |
0.4 |
|
| 1995 |
Cohen R, Jaffe ES, Stetler-Stevenson MA, Sausville EA, DeNigris EC, Woodworth T, Foss FM. Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB486 interleukin-2). Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 16: 229-33. PMID 7834123 DOI: 10.1097/00002371-199410000-00008 |
0.44 |
|
| 1995 |
Kuchnio M, Sausville EA, Jaffe ES, Greiner T, Foss FM, McClanahan J, Fukushima P, Stetler-Stevenson MA. Flow cytometric detection of neoplastic T cells in patients with mycosis fungoides based on levels of T-cell receptor expression. American Journal of Clinical Pathology. 102: 856-60. PMID 7801904 DOI: 10.1093/Ajcp/102.6.856 |
0.385 |
|
| 1995 |
Koh HK, Jacobson JO, Foss F, Lew RA. Is Cutaneous T-Cell Lymphoma Curable? Archives of Dermatology. 131: 1081-1082. PMID 7661616 DOI: 10.1001/Archderm.1995.01690210113022 |
0.395 |
|
| 1995 |
Foss FM, Kuzel TM. Experimental Therapies in the Treatment of Cutaneous T-cell Lymphoma Hematology/Oncology Clinics of North America. 9: 1127-1137. DOI: 10.1016/S0889-8588(18)30063-7 |
0.454 |
|
| 1995 |
Rosen ST, Foss FM. Chemotherapy for Mycosis Fungoides and the Sézary Syndrome Hematology/Oncology Clinics of North America. 9: 1109-1116. DOI: 10.1016/S0889-8588(18)30061-3 |
0.377 |
|
| 1995 |
Foss FM, Sausville EA. Prognosis and Staging of Cutaneous T-cell Lymphoma Hematology/Oncology Clinics of North America. 9: 1011-1019. DOI: 10.1016/S0889-8588(18)30055-8 |
0.321 |
|
| 1994 |
Foss FM, Koc Y, Stetler-Stevenson MA, Nguyen DT, O'Brien MC, Turner R, Sausville EA. Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sézary syndrome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 326-35. PMID 8113839 DOI: 10.1200/Jco.1994.12.2.326 |
0.367 |
|
| 1994 |
Foss FM, Ihde DC, Linnoila IR, Fischmann AB, Schechter GP, Cotelingam JD, Steinberg SM, Ghosh BC, Stocker JL, Bastian A. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 2051-9. PMID 7931473 DOI: 10.1200/Jco.1994.12.10.2051 |
0.369 |
|
| 1994 |
Foss F, Borkowski T, Gilliom M, Stetler-Stevenson M, Jaffe E, Figg W, Tompkins A, Bastian A, Nylen P, Woodworth T. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study Blood. 84: 1765-1774. DOI: 10.1182/Blood.V84.6.1765.Bloodjournal8461765 |
0.378 |
|
| 1993 |
Cohen RB, Abdallah JM, Gray JR, Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Annals of Internal Medicine. 118: 114-6. PMID 8416307 DOI: 10.7326/0003-4819-118-2-199301150-00007 |
0.379 |
|
| 1993 |
Graham SJ, Sharpe RW, Steinberg SM, Cotelingam JD, Sausville EA, Foss FM. Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sezary syndrome Cancer. 72: 726-734. PMID 8334625 DOI: 10.1002/1097-0142(19930801)72:3<726::Aid-Cncr2820720316>3.0.Co;2-P |
0.353 |
|
| 1992 |
Foss FM, Ihde DC, Breneman DL, Phelps RM, Fischmann AB, Schechter GP, Linnoila I, Breneman JC, Cotelingam JD, Ghosh BC. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 10: 1907-13. PMID 1453206 DOI: 10.1200/Jco.1992.10.12.1907 |
0.384 |
|
| 1989 |
Kaye FJ, Bunn PA, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, Glatstein EJ, Schechter GP, Phelps RM, Foss FM. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. The New England Journal of Medicine. 321: 1784-90. PMID 2594037 DOI: 10.1056/Nejm198912283212603 |
0.398 |
|
| Show low-probability matches. |